SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-278946
Filing Date
2023-11-16
Accepted
2023-11-16 17:16:52
Documents
14
Period of Report
2023-11-16
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d576980d8k.htm   iXBRL 8-K 23293
2 EX-5.1 d576980dex51.htm EX-5.1 47861
6 GRAPHIC g576980g1116084339033.jpg GRAPHIC 1530
  Complete submission text file 0001193125-23-278946.txt   200877

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rprx-20231116.xsd EX-101.SCH 2857
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rprx-20231116_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rprx-20231116_pre.xml EX-101.PRE 10817
8 EXTRACTED XBRL INSTANCE DOCUMENT d576980d8k_htm.xml XML 3236
Mailing Address 110 EAST 59TH STREET NEW YORK NY 10022
Business Address 110 EAST 59TH STREET NEW YORK NY 10022 (212) 883-0200
Royalty Pharma plc (Filer) CIK: 0001802768 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39329 | Film No.: 231415549
SIC: 2834 Pharmaceutical Preparations